142 related articles for article (PubMed ID: 15494716)
1. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S
Br J Cancer; 2004 Nov; 91(9):1651-5. PubMed ID: 15494716
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
3. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
Wolff AC; Donehower RC; Carducci MK; Carducci MA; Brahmer JR; Zabelina Y; Bradley MO; Anthony FH; Swindell CS; Witman PA; Webb NL; Baker SD
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3589-97. PubMed ID: 14506145
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Lara PN; Frankel P; Mack PC; Gumerlock PH; Galvin I; Martel CL; Longmate J; Doroshow JH; Lenz HJ; Lau DH; Gandara DR
Clin Cancer Res; 2003 Oct; 9(12):4356-62. PubMed ID: 14555506
[TBL] [Abstract][Full Text] [Related]
7. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
13. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
20. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
